New Lower-Dose combo aims to tame tough lymphoma, pave way for transplant
NCT ID NCT07451652
Summary
This study is testing if a lower dose of the drug epcoritamab, when combined with standard chemotherapy drugs, can help control aggressive lymphoma that has returned or not responded to prior treatment. The goal is to shrink the cancer enough so patients can safely proceed with a stem cell transplant, a potentially curative next step. Researchers will closely monitor how well the treatment works and its side effects in a small group of eligible patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Universitario "Dr. José Eleuterio González"
RECRUITINGMonterrey, Nuevo León, 64640, Mexico
Conditions
Explore the condition pages connected to this study.